New drugs and combinations in the palliative treatment of colon and rectal cancer

被引：10

作者：

Beretta, GD ^{[1
]}

Pessi, MA ^{[1
]}

Poletti, P ^{[1
]}

Mosconi, S ^{[1
]}

Labianca, R ^{[1
]}

机构：

[1] Osped Riuniti Bergamo, Med Oncol Unit, I-24100 Bergamo, Italy

来源：

EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 2001年 / 27卷 / 06期

关键词：

colorectal cancer; chemotherapy;

D O I：

10.1053/ejso.2001.1128

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer (CRC) is a common disease. The overall survival has improved only marginally in recent decades despite advances in surgery and early detection. Potentially curative resection at disease presentation can be performed only in 70-80% of the patients, and overall survival at 5 years is less than 60%. Advanced disease is associated with a poor prognosis. Treatment for advanced colorectal cancer has nevertheless made progress in the last few years. Systemic chemotherapy doubles the survival of these patients compared to untreated controls. Chemotherapy has demonstrated effective palliation, improvement of quality of life (QoL) and symptom improvement in such patients. For nearly four decades, fluorouracil (5FU) has been the mainstay of treatment. New compounds active against colorectal cancer are now available. Several studies on this topic are ongoing. (C) 2001 Harcourt Publishers Ltd.

引用

页码：595 / 600

页数：6

共 33 条

[1]

Beretta G, 1997, P AN M AM SOC CLIN, V16, p259a

[2]

Cao S, 1997, P AN M AM SOC CLIN, V16, p226a

[3] Final results of a randomised trial comparing 'Tomudex'(R) (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer [J].

Cunningham, D ;

Zalcberg, JR ;

Rath, U ;

Oliver, I ;

vanCutsem, E ;

Svensson, C ;

Seitz, JF ;

Harper, P ;

Kerr, D ;

PerezManga, G .

ANNALS OF ONCOLOGY, 1996, 7 (09) :961-965

[4] Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer [J].

Cunningham, D ;

Pyrhönen, S ;

James, RD ;

Punt, CJA ;

Hickish, TF ;

Heikkila, R ;

Johannesen, TB ;

Starkhammar, H ;

Topham, CA ;

Awad, L ;

Jacques, C ;

Herait, P .

LANCET, 1998, 352 (9138) :1413-1418

[5]

Cvitkovic E, 1999, SEMIN ONCOL, V26, P647

[6]

DEGRAMONT A, 1998, P AN M AM SOC CLIN, V17, P257

[7] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

[8] Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer [J].

Giacchetti, S ;

Perpoint, B ;

Zidani, R ;

Le Bail, N ;

Faggiuolo, R ;

Focan, C ;

Chollet, P ;

Llory, JF ;

Letourneau, Y ;

Coudert, B ;

Bertheaut-Cvitkovic, F ;

Larregain-Fournier, D ;

Le Rol, A ;

Walter, S ;

Adam, R ;

Misset, JL ;

Lévi, F .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :136-147

[9] Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery [J].

Giacchetti, S ;

Itzhaki, M ;

Gruia, G ;

Adam, R ;

Zidani, R ;

Kunstlinger, F ;

Brienza, S ;

Alafaci, E ;

Bertheault-Cvitkovic, F ;

Jasmin, C ;

Reynes, M ;

Bismuth, H ;

Misset, JL ;

Lévi, F .

ANNALS OF ONCOLOGY, 1999, 10 (06) :663-669

[10] EXPECTANCY OR PRIMARY CHEMOTHERAPY IN PATIENTS WITH ADVANCED ASYMPTOMATIC COLORECTAL-CANCER - A RANDOMIZED TRIAL [J].

GLIMELIUS, B ;

PAHLMAN, L ;

GRAF, W ;

ADAMI, HO ;

TVEIT, K ;

HANSEN, J ;

LILJEGREN, G ;

DOMELoF, L ;

LJUNGQVIST, U ;

BERGMAN, L ;

ENANDER, LK ;

UNDERSKOG, I ;

SoDERBERG, M ;

JoNSSON, PE ;

HAFSTRoM, L ;

HEUMAN, R ;

ATHLIN, L ;

SASSNER, P ;

SELLSTRoM, H .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (06) :904-911

← 1 2 3 4 →